Privium Fund Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-58,709
| Closed | -$417K | – | 61 |
|
|
2025
Q1 | $417K | Buy |
58,709
+31,000
| +112% | +$220K | 0.11% | 46 |
|
|
2024
Q4 | $323K | Buy |
27,709
+15,409
| +125% | +$180K | 0.07% | 52 |
|
|
2024
Q3 | $253K | Buy |
+12,300
| New | +$253K | 0.06% | 69 |
|
|
2024
Q2 | – | Sell |
-8,905
| Closed | -$245K | – | 133 |
|
|
2024
Q1 | $245K | Hold |
8,905
| – | – | 0.07% | 80 |
|
|
2023
Q4 | $274K | Hold |
8,905
| – | – | 0.08% | 65 |
|
|
2023
Q3 | $282K | Hold |
8,905
| – | – | 0.08% | 65 |
|
|
2023
Q2 | $364K | Hold |
8,905
| – | – | 0.1% | 63 |
|
|
2023
Q1 | $332K | Buy |
8,905
+1,615
| +22% | +$60.2K | 0.11% | 58 |
|
|
2022
Q4 | $257K | Buy |
7,290
+2,000
| +38% | +$70.6K | 0.1% | 66 |
|
|
2022
Q3 | $292K | Buy |
5,290
+1,250
| +31% | +$69K | 0.11% | 69 |
|
|
2022
Q2 | $209K | Buy |
+4,040
| New | +$209K | 0.07% | 91 |
|